EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Evaluation of the effectiveness and safety of ONO ‐2910 for the treatment of diabetic polyneuropathy: An early Phase IIa , multicenter, randomized, placebo‐controlled, double‐blind study in Japanese patients

Yukiko Onishi iD, Takeshi Osonoi, Norio Takahashi, Toru Takiguchi, Eiichiro Morishima, Yoshimasa Aso iD, Kenji Sekiguchi, Hideki Kamiya, Jiro Nakamura iD

Journal of Diabetes Investigation · 2026

DOI: 10.1111/jdi.70193 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes Investigation, 2026. Verfasst von Yukiko Onishi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Tokyo, Japan. Hauptthemen laut MEDLINE: Diabetic Neuropathies, Diabetes Mellitus, Type 2. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ono Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction Diabetic polyneuropathy (DPN) is common in patients with diabetes. Its symptoms include pain, numbness, and impaired neurosensory function. ONO‐2910 promotes Schwann cell differentiation and is being developed for DPN. Materials and Methods This Phase IIa randomized controlled trial evaluated the effectiveness and safety of ONO‐2910 in Japanese patients with type 2 diabetes and DPN. Patients were randomized to ONO‐2910 (300 mg/day) or placebo, once daily, for 12 weeks. The primary endpoints were the changes in the sum scores for numbness and tingling (modified Toronto Clinical Neuropathy Scores [mTCNS]) and safety.

Results

The ONO‐2910 and placebo groups comprised 76 (safety: 77 patients) and 77 patients, respectively. The mean (standard deviation) age and time since DPN diagnosis were 62.6 (8.48) and 4.89 (5.662) years, respectively. The least‐squares mean (LSM) change in mTCNS sum scores for numbness and tingling at 12 weeks was −1.0 in both groups (LSM difference: 0.0; 95% confidence interval −0.4 to 0.4). The LSM changes in the mTCNS total scores were −2.6 (0.64) and −2.3 (0.67) in the ONO‐2910 and placebo groups, respectively. There were no marked changes in nerve function and nerve conduction velocities in the ONO‐2910 and placebo groups. Treatment‐emergent adverse events (TEAEs) occurred in 37 (48.1%) and 39 (50.6%) patients in the ONO‐2910 and placebo groups, respectively. TEAEs in ≥2 patients in the ONO‐2910 group were nasopharyngitis (5 patients), diarrhea (3 patients), nausea (2 patients), and eczema (2 patients).

Conclusions

ONO‐2910 was generally well‐tolerated in Japanese patients with DPN. There were no obvious improvements in DPN symptoms or neurosensory function among patients who received ONO‐2910 versus placebo. Clinical Trial Registry Japan Primary Registries Network jRCT2061210008

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NeuropathiesDiabetes Mellitus, Type 2HumansFemaleMaleMiddle AgedDouble-Blind MethodAgedJapanTreatment OutcomePrognosisFollow-Up StudiesEast Asian People

Stichwörter der Autor:innen

Diabetes mellitusPolyneuropathySchwann cells

Autor:innen und Institutionen

  • Division of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Tokyo, Japan.
  • Nakakinen Clinic, Ibaraki, Japan.
  • Department of Endocrinology and Diabetes, Nagoya Ekisaikai Hospital, Nagoya, Japan.
  • Department of Clinical Development, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
  • Dokkyo Medical University Hospital, Tochigi, Japan.
  • Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Japan.

ORCID-Profile: Yukiko Onishi, Yoshimasa Aso, Jiro Nakamura

Förderung

  • Ono Pharmaceutical

Zitieren

APA

Onishi, Y., Osonoi, T., Takahashi, N., Takiguchi, T., Morishima, E., Aso, Y., Sekiguchi, K., Kamiya, H., & Nakamura, J. (2026). Evaluation of the effectiveness and safety of ONO ‐2910 for the treatment of diabetic polyneuropathy: An early Phase IIa , multicenter, randomized, placebo‐controlled, double‐blind study in Japanese patients. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70193

Vancouver

Onishi Y, Osonoi T, Takahashi N, Takiguchi T, Morishima E, Aso Y, et al. Evaluation of the effectiveness and safety of ONO ‐2910 for the treatment of diabetic polyneuropathy: An early Phase IIa , multicenter, randomized, placebo‐controlled, double‐blind study in Japanese patients. Journal of Diabetes Investigation. 2026. doi:10.1111/jdi.70193

BibTeX
@article{Onishi2026,
  author = {Onishi, Yukiko and Osonoi, Takeshi and Takahashi, Norio and Takiguchi, Toru and Morishima, Eiichiro and Aso, Yoshimasa and Sekiguchi, Kenji and Kamiya, Hideki and Nakamura, Jiro},
  title = {Evaluation of the effectiveness and safety of ONO ‐2910 for the treatment of diabetic polyneuropathy: An early Phase IIa , multicenter, randomized, placebo‐controlled, double‐blind study in Japanese patients},
  journal = {Journal of Diabetes Investigation},
  year = {2026},
  doi = {10.1111/jdi.70193}
}
Kostenlos starten →